Pharsight

1. List of Apretude drug patents

Application	Filing Date	Opposition Party	Legal Status
EP17195280A	2020-02-04	Gilead Sciences, Inc.	Opposition rejected
EP16154531A	2018-12-06	Gilead Sciences, Inc.	Patent maintained as amended
EP06822311A	2016-11-24	Zwicker Schnappauf & Partner PartG mbB	Opposition procedure closed
EP06758843A	2014-05-28	Ahrens, Gabriele	Opposition procedure closed

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8410103	VIIV HLTHCARE	(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent	Apr, 2026 (3 years from now)
US10927129	VIIV HLTHCARE	N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity	Apr, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224597	VIIV HLTHCARE	Pharmaceutical compositions	Sep, 2031 (8 years from now)